Dyshormonogenesis

Overview

General Features

• Accounts for 10-15% of permanent congenital hypothyroidism (CH).
• Inheritance: Autosomal Recessive.
• Pathophysiology: Impaired hormone synthesis -> Decreased circulating T4/T3 -> Lack of negative feedback -> Increased TSH secretion -> Compensatory thyroid hyperplasia (Goiter).
• Goiter visible in utero, at birth, or later in childhood depending on severity.
• Diagnosis established via scintigraphy, perchlorate discharge test, and biochemical markers.

Genetic Defects of Biosynthesis

Detailed Pathophysiology of Specific Defects

1. Sodium-Iodide Symporter (NIS) Defect

• Gene: SLC5A5.
• Mechanism: Failure to actively concentrate iodide from circulation into follicular cells.
• Scintigraphy: Low or absent uptake of radioiodine/pertechnetate in thyroid gland. May mimic thyroid agenesis.
• Differentiation: Absent normal salivary gland and gastric mucosa iodine uptake. Decreased saliva:serum 123I ratio confirms diagnosis.
• Clinical: Variable onset (neonatal to childhood). May respond to massive iodide doses, but levothyroxine preferred.

2. Pendred Syndrome (SLC26A4 Defect)

• Gene: SLC26A4 (encodes Pendrin).
• Mechanism: Impaired apical iodide transport into colloid, leading to partial organification defect.
• Syndromic Features: Congenital bilateral sensorineural deafness.
• Thyroid Phenotype: Usually mild. Variable onset of goiter and hypothyroidism, heavily dependent on nutritional iodine intake.
• Testing: Positive perchlorate discharge test ^[1] indicates impaired organification.

3. Thyroperoxidase (TPO) Defect

• Gene: TPO.
• Epidemiology: Most common dyshormonogenesis defect in Caucasian populations.
• Mechanism: Complete or partial failure to oxidize and incorporate iodide into TG tyrosine residues, or failure to couple iodotyrosines.
• Scintigraphy: High radioiodine uptake.
• Testing: Hallmark is marked discharge of radioiodine (40-90%) upon administration of perchlorate^[1:1] or thiocyanate 2 hours after tracer dose. Normal individuals exhibit <10% discharge.
• Biochemical: Markedly elevated serum TG. Severe goitrous CH.

4. H2O2 Generation Defects (DUOX2 and DUOXA2)

• Genes: DUOX2 (Dual oxidase 2) and DUOXA2 (Maturation factor).
• Epidemiology: Most common dyshormonogenesis cause in Asian populations.
• Mechanism: Rate-limiting step for TG iodination impaired due to lack of local H2O2 generation at apical membrane.
• Clinical Phenotype: Extremely variable. Ranges from life-threatening in utero goiter to permanent CH, to transient CH, to life-long euthyroidism. Variable compensation by DUOX1 postulated.

5. Thyroglobulin (TG) Synthesis Defect

• Gene: TG.
• Mechanism: Structural defects in TG glycoprotein. Impaired folding, defective intracellular transport, restricted access to tyrosine residues, or impaired coupling.
• Clinical: Goitrous CH presenting in utero or at birth.
• Biochemical: Characterized by low or undetectable serum TG levels, unlike other forms of dyshormonogenesis where TSH-stimulated TG is elevated.

6. Dehalogenase (Iodotyrosine Deiodinase) Defect

• Gene: IYD (formerly DEHAL1).
• Mechanism: Failure to deiodinate uncoupled MIT and DIT within follicular cell.
• Pathophysiology: Iodotyrosines leak into circulation and are lost in urine. Leads to rapid, severe, continuous state of iodine deficiency.
• Biochemical Hallmark: Elevated urinary excretion of MIT and DIT.
• Clinical: Goitrous CH. Severity varies with dietary iodine intake.

DIAGNOSTIC EVALUATION OF DYSHORMONOGENESIS

1. Newborn Screening and Initial Labs

• Screening: Detected via high TSH (>15-30 mU/L) on filter paper spot.
• Confirmatory Serum: Elevated TSH, low Free T4 (FT4).
• Thyroglobulin (TG): Elevated in most dyshormonogenesis (due to TSH stimulation). Low/undetectable specifically indicates TG synthesis defect or TSH receptor defect/thyroid agenesis.

2. Imaging Studies

• Ultrasonography: Confirms presence of normally located (orthotopic) gland. Demonstrates normal size or goitrous enlargement.
• Scintigraphy (Radionuclide Scan): 123I (preferred) or 99mTc pertechnetate.
  • Normal/High uptake: Confirms functional NIS. Points towards TPO, DUOX2, Pendrin, or TG defects.
  • Absent uptake: Indicates NIS (SLC5A5) defect, TSH-receptor blocking antibodies, or TSH-receptor mutations (despite gland presence on ultrasound).

3. Perchlorate Discharge Test

• Administer radioiodine, measure uptake at 2 hours.
• Administer potassium perchlorate (competitive inhibitor of NIS).
• Rapid release (discharge) of >10% of accumulated tracer indicates organification defect (TPO, DUOX2, Pendrin). Trapped iodine remains unbound and washes out.

4. Genetic Testing

• Confirms precise etiology.
• Seldom alters immediate levothyroxine management but crucial for familial counseling (25% recurrence risk for autosomal recessive traits).

MANAGEMENT PRINCIPLES

• Immediate Initiation: Levothyroxine (L-T4) therapy at 10-15 μg/kg/day to rapidly normalize FT4 and suppress TSH.
• Goiter Reduction: Suppressive L-T4 doses minimize TSH-driven thyromegaly, preventing airway obstruction.
• Outcome: Normal physical and intellectual development if initiated promptly.

Thyroid Dysgenesis

Overview

• Most common cause of permanent congenital hypothyroidism (CH).
• Accounts for 80-85% of CH cases globally; 75% of cases in India.
• Characterized by abnormal formation of the thyroid gland during embryogenesis.
• Typically sporadic occurrence; 1% familial incidence confers 40-fold increased risk.
• High discordance in monozygotic twins suggests two-hit pathogenesis model (germline susceptibility combined with somatic postzygotic event).

Anatomical Subtypes

Genetic & Molecular Etiology

Genetic defects in transcription factors essential for thyroid morphogenesis account for 2-5% of cases, often presenting with syndromic features.

Clinical Manifestations

• Infants often completely asymptomatic at birth due to protective transplacental maternal T4 transfer.
• Neonatal Signs: Large open anterior and posterior fontanels, macroglossia, umbilical hernia, prolonged jaundice (delayed glucuronide conjugation), hypotonia, hypothermia.
• Infancy Symptoms: Lethargy, poor feeding, choking spells, hoarse cry, mottling of skin, constipation.
• Late Findings (if untreated): Severe growth stunting, delayed psychomotor milestones, profound intellectual disability, myxedema, coarse/brittle hair, depressed nasal bridge.
• Ectopic Thyroid Presentation: May present in later childhood as growing midline neck or base-of-tongue mass.

Investigations & Diagnosis

• Newborn Screening: Hallmark finding is elevated TSH with low free T4 (FT4).
• Radionuclide Scintigraphy (99mTc or 123I): Gold standard imaging. Demonstrates exact location of ectopic tissue or confirms complete absence of uptake (agenesis, TSHR defects, maternal blocking antibodies).
• Neck Ultrasound: Confirms absence of normally located gland. Highly user-dependent; frequently misses ectopic glands.
• Serum Thyroglobulin (Tg): Low or undetectable in true agenesis and TSHR defects; characteristically elevated in ectopy.
• Bone Radiography: Absent distal femoral and proximal tibial epiphyses in term infants confirms prenatal onset of hypothyroidism.

Management & Prognosis

• Primary Goal: Rapid restoration of euthyroidism to prevent irreversible neurodevelopmental damage and intellectual disability.
• Pharmacotherapy: Oral Levothyroxine (L-T4) is the treatment of choice.
• Timing & Dosing: Initiate promptly, ideally by 2 weeks of life. Starting dose: 10-15 mcg/kg/day.
• Monitoring Targets: Maintain TSH strictly within age-specific reference ranges; target FT4 levels in upper half of normal range.
• Surgical Intervention: Excision of sublingual/ectopic thyroid generally unnecessary; ectopic tissue typically becomes atrophic upon initiation of L-T4 suppressive therapy.
• Genetic Counseling: Indicated for families presenting with syndromic features or established inheritance patterns.